
Liquidia Corp Investor Relations Material
Latest events

Q1 2025
Liquidia Corp
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Liquidia Corp
Access all reports
Liquidia Corp. is a biopharmaceutical company focused on developing and commercializing innovative therapies for pulmonary and other rare diseases. The company utilizes its proprietary PRINT technology to engineer precise drug particles designed to improve the delivery and efficacy of inhaled treatments. Liquidia's primary focus is on addressing unmet medical needs in pulmonary arterial hypertension (PAH) and other related conditions. The company is involved in advancing its therapies through clinical trials and regulatory approvals, aiming to provide improved treatment options for patients with chronic, life-threatening illnesses. The company is headquartered in Morrisville, North Carolina, and its shares are listed on the NASDAQ.
Key slides for Liquidia Corp


43rd Annual J.P. Morgan Healthcare Conference 2025
Liquidia Corp


43rd Annual J.P. Morgan Healthcare Conference 2025
Liquidia Corp
Latest articles
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
Ticker symbol
LQDA
Country
🇺🇸 United States